Articles By Wayne Koberstein, Executive Editor

Companies To Watch: CytoAgents
CytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.  Continue Reading..
  • The Discovering CEO

    In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.

  • Companies To Watch: Viking Therapeutics

    Viking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.

  • Nonprofit Pursues Oncology Drugs

    RebootRX believes that many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.

  • Companies To Watch: Priothera

    Priothera is bent on boosting the safety and effectiveness of hematopoietic stem cell transplantation for blood cancers.

  • Living Diversity, Inside Mink Therapeutics

    We sought out a biopharma enterprise where diversity always has been an operating principle, where it feeds the company’s intellectual life and creative culture, and where it is demonstrable yet still evolving.

  • Companies To Watch: Mirum Pharmaceuticals

    Mirum Pharmaceuticals: Two drugs, one FDA approved, together taking on a half-dozen rare liver diseases.

  • New Space For Bio In Transplantation

    Jasper Therapeutics and other bio companies may revolutionize hematopoietic stem cell therapy (HSCT) — a feat with profound effects on the biopharma and hospital-based hematology sectors alike.

  • Companies To Watch: CinCor Pharma

    CinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.

  • CoCrystal’s Co-CEOs

    Most biopharma industry observers would agree the leadership of a company by two co-equal CEOs is a rare thing. But when it does happen, the unusual arrangement offers useful insights.

  • Companies To Watch: Castle Creek Biosciences

    For Castle Creek Biosciences, there are many stakes at play in targeting rare skin, connective tissue, liver, and metabolic disorders.

  • Platforms To Pipelines: Part 2

    In part 2 of this series, we cover each company’s future plans, as well as their leaders’ observations of the platform-to-pipeline space they are effectively expanding, by joining a gathering crowd of companies now entering it.

  • Beyond Profits To Biopharma Innovation

    What if, for certain ambitious but traditionally underfunded areas needing innovation, a startup could achieve its ends without the usual for-profit incentives?

  • Companies To Watch: Global Blood Therapeutics

    Global Blood Therapeutics is intertwining science, business, and social missions to make progress against sickle cell disease.

  • Platforms To Pipelines: Part 1

    To discover why companies go about transforming themselves from technology suppliers into biotherapeutics developers, we spoke with the heads of five companies built upon novel platforms for discovery or development of new biotherapeutics, though at various stages and differences in applied strategies.

wayne koberstein

Wayne Koberstein

Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.